ATIMOS

This brand name is authorized in Estonia, Germany, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Tunisia, UK.

Active ingredients

The drug ATIMOS contains one active pharmaceutical ingredient (API):

1	Formoterol fumarate dihydrate UNII W34SHF8J2K - FORMOTEROL FUMARATE
	Formoterol is a predominantly selective β2-stimulator. Formoterol has bronchodilator activity in patients with reversible obstructive airway diseases. In humans formoterol is effective in the prophylaxis of bronchospasm induced by methacholine challenge.
	Read more about Eformoterol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATIMOS MODULITE Pressurised inhalation solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AC13	Formoterol	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AC Selective beta-2-adrenoreceptor agonists
Discover more medicines within R03AC13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	10420789, 11600306, 17602424
EE	Ravimiamet	1227596, 1227619, 1227620
GB	Medicines & Healthcare Products Regulatory Agency	377157, 96288
IT	Agenzia del Farmaco	035791058
LT	Valstybinė vaistų kontrolės tarnyba	1004792, 1022318, 1026213
NL	Z-Index G-Standaard	13638378
NL	Z-Index G-Standaard, PRK	73350
PL	Rejestru Produktów Leczniczych	100163874
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63349001, W63349002, W63349003
SG	Health Sciences Authority	13761P
TN	Direction de la Pharmacie et du Médicament	7133051